Cerevance to Participate at the SVB Global Biopharma Conference
BOSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced that Craig Thompson, chief executive officer of Cerevance, will participate in the upcoming SVB Global Biopharma Conference. The conference is being held virtually January 31 February 2, 2023.
Cerevance is a private pharmaceutical company with a focus on CNS disorders. CVN424, Cerevances lead therapeutic, is a first-in-class, oral, non-dopaminergic compound acting on a novel target (GPR6), demonstrated significant and clinically meaningful efficacy in a 135-patient Phase 2 study in patients with Parkinsons disease. The company uses its proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform to identify highly selectively expressed, novel target proteins that are either specific to certain brain circuits or are over- or under-expressed in diseased brains. Partnering with over 25 brain banks and evaluating more than 12,000 human post-mortem brain tissue samples, Cerevance is advancing a robust pipeline of targeted treatments for patients with neurodegenerative diseases, including Parkinsons disease, Amyotrophic Lateral Sclerosis and Alzheimers disease. For additional information, please visit www.cerevance.com.
Johnna Simoes, email@example.com
Andrew Mielach, firstname.lastname@example.org, +1-646-876-5868
Continue read on globenewswire.com